ATR and breast carcinoma: To illustrate the advantage of HTSplotter on drug combination evaluation assessed in real-time, we applied our tool to an in-house assessment of the human breast cancer cell line MCF-7 in response to single and combination exposure to three inhibitors targeting WEE1, CHK1 and ATR (MK-1775, prexasertib and BAY1895344, respectively) (S4 Fig).